Ask about this productRelated genes to: CD44 antibody
- Gene:
- CD44 NIH gene
- Name:
- CD44 molecule (Indian blood group)
- Previous symbol:
- MIC4, MDU2, MDU3
- Synonyms:
- IN, MC56, Pgp1, CD44R, HCELL, CSPG8
- Chromosome:
- 11p13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2019-04-23
Related products to: CD44 antibody
Related articles to: CD44 antibody
- B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated substantial clinical benefit in relapsed/refractory multiple myeloma (R/R MM). Nonetheless, immune escape and therapeutic resistance remain major challenges, and the molecular features of residual disease have not been fully elucidated. - Source: PubMed
Publication date: 2026/05/14
Chen XinzhuoZhang JingjingChen HuiHuang RenhuaZhou XiaoxiaoWang HuipingXiao HaoPeng QianWu FanZhai ZhiminWang Zhitao - Bone formation is a complex process involving multiple cell types and molecular signals that regulate osteogenesis from three embryological origins. Depending on the anatomical site, bone develops through either intramembranous or endochondral ossification. Although skeletal development has been extensively studied, the spatial and temporal expression of proteins during endochondral ossification, particularly according to anatomical site and cellular compartment, remains incompletely understood. In this descriptive study, we evaluated the in-situ expression of cell surface proteins previously described as mesenchymal stem cell markers-other than those proposed by the International Society for Cellular Therapy (CD105, CD90, and CD73)-during human skeletal development. Protein expression was analyzed in a spatiotemporal manner during endochondral ossification in axial and appendicular skeletal elements from human embryos, fetuses, and post-term individuals across the three trimesters of gestation. Our findings identified strong expression of CD166, CD271, and Podoplanin in chondroblasts of vertebral bodies and mesenchymal cells of the autopod during the first trimester. In contrast, CD146, CD29, CD44, and STRO-1 were not detected in the first trimester but appeared after week 13, predominantly within the extracellular matrix; therefore, not associated with early osteochondroprogenitors. Overall, this study provides novel insights into the anatomical and developmental distribution of seven cell surface markers during human skeletogenesis. Notably, these proteins were detected in cellular compartments beyond the plasma membrane, including the extracellular matrix, and exhibited distinct spatial and temporal expression patterns during gestation. - Source: PubMed
Publication date: 2026/05/12
Arbeláez-Teuzaba Juan SebastiánCastro Derna LuzFranco-Zuluaga Jorge AndrésNiño-Traslaviña KatherinGuevara-Morales Johana MaríaAlmaciga-Díaz Carlos JavierOlaya-C MercedesGutiérrez-Gómez María Lucía - Glioblastoma multiforme (GBM) is a lethal and fast-growing brain cancer that is difficult to treat with standard medical interventions. GBM tumors often overexpress cyclin-dependent kinase 9, in complex with cyclin T1, and thus, it represents a promising target for therapeutic intervention. In this study, we employed a structure-based virtual screening approach for a curated library of 6,059 bis-pyridyl compounds from PubChem to identify potential CDK9/T1 inhibitors. Subsequent ADP-Glo assay led to the identification of GNE-3511 as a potent CDK9/T1 inhibitor with an IC of 0.064 μM. GNE-3511 also inhibited CDK7/cyclin H with an IC of 0.12 μM. In U-87 MG and T98G glioblastoma cells, GNE-3511 exhibited cytotoxicity with a GI of 3.4 and 5.0 μM, inducing G2/M phase cell cycle arrest and promoting early apoptosis. Treatment with GNE-3511 significantly reduced the expression of the anti-apoptotic markers BCL-2, SURVIVIN and drug resistance markers ( and ) in a dose-dependent manner, and downregulated glioma stem cell population/markers (, CD90, or CD133 and ) and sphere formation abilities. Oral administration of GNE-3511 at 20 mg/kg (twice daily) demonstrated significant anti-tumor efficacy and improved survival in both U-87 MG and T98G xenograft/orthotopic mouse models. Collectively, these findings highlight GNE-3511 as a promising lead candidate for the development of GBM therapeutics. - Source: PubMed
Publication date: 2026/05/14
Pr Nithya SreeSomarowthu TejaswiS JeyasankariKuncha MadhusudhanaAndugulapati Sai BalajiBharate Sandip B - Kidney stones (KS) represent a complex and globally prevalent disease; however, the mechanisms underlying their formation are not fully understood. Inflammatory responses and crystal aggregation are recognized as critical factors in KS pathogenesis. Interleukin-6 (IL-6) is widely recognized as an inflammatory mediator; however, its precise contribution to calcium oxalate (CaOx) KS formation has not been fully elucidated. This study aimed to explore the detailed mechanism through which IL-6 influences CaOx KS formation. To achieve this, a rat model for CaOx nephrolithiasis was developed by administrating drinking water containing 1% ethylene glycol (EG). Concurrently, an in vitro model of cellular injury was established by treating human renal proximal tubular epithelial cells (HK-2) with calcium oxalate monohydrate (COM) crystals. Employing various molecular biology and immunological techniques, the specific role of IL-6 in the formation of CaOx stones was comprehensively examined. The data indicated significantly elevated IL-6 expression in both in vivo and in vitro models of CaOx KS. Increased IL-6 exacerbated inflammatory responses during stone formation, triggered activation of the p38 MAPK signaling pathway, and promoted higher expression levels of osteopontin (OPN) and CD44. These molecular alterations enhanced adhesion between renal tubular epithelial cells (RTECs) and crystals, consequently facilitating crystal aggregation, nucleation, and accelerating overall stone formation. In summary, the study illustrates that IL-6 accelerates CaOx KS development through activation of the p38 MAPK signaling pathway, amplifying inflammation, and promoting crystal-cell adhesion. Thus, IL-6 emerges as a promising therapeutic target for interventions in CaOx nephrolithiasis. - Source: PubMed
Publication date: 2026/05/14
Liang FujieGuo FuYouHan ZepingXiang YouGuan XiaoFengWang Xiang - Metabolic reprogramming is a pivotal driver of tumor microenvironment (TME) remodeling and colorectal cancer (CRC) progression. However, the spatial organization of glycolysis heterogeneity and the molecular drivers maintaining the malignant high-glycolytic state remain poorly understood. - Source: PubMed
Publication date: 2026/04/28
Yang FengmingBian YinuoJin YuqiTan YinuoLao TianhaoYang JieChen Hua